Arezoo Faridzadeh

Arezoo Faridzadeh

Auto-generated profile, based on publicly available information

Arezoo Faridzadeh

Immunology Research Center Mashhad University of Medical Sciences Mashhad Iran

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MSMaryam Sadri
Maryam Sadri
SHSahel Heidari
Sahel Heidari
AFArezoo Faridzadeh
Arezoo Faridzadeh
MRMona Roozbehani
Mona Roozbehani
STShirin Toosi
Shirin Toosi
FFFatemeh Faraji
Fatemeh Faraji
Immunotherapy has improved cancer treatment based on investigations of tumor immune escape. Manipulation of the immune system stimulates antitumor immune responses and blocks tumor immune escape routes. Genetically adoptive cell therapy, such as T cells, has yielded promising results for hematologic malignancies, but their application to solid tumors has been challenging. Macrophages have a wide broad of capabilities in regulating immune responses, homeostasis, and tissue development, as well as the ability to phagocyte, present antigens, and infiltrate the tumor microenvironment (TME). Given the importance of macrophages in cancer development, they could serve as novel tool for tumor treatment. Therefore, macrophages are used in different formats for direct and indirect targeting of tumor cells. This review summarized the available data on the various applications of macrophages in cancer immunotherapy.

23 October 2023 in Health Science Reports
Verified
Journal Article
Open access
ZMZahra Mirfeizi
Zahra Mirfeizi
MMMahmoud Mahmoudi
Mahmoud Mahmoudi
AFArezoo Faridzadeh
Arezoo Faridzadeh
Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that primarily affects young women. SLE has no recognized etiology but it is believed to be triggered by a number of factors, including genetic predisposition, hormonal influences, and environmental conditions. Dysbiosis in the gut microbiota has emerged as a potential mechanism connecting the intestinal microbiome to the breakdown of self‐tolerance and chronic inflammation. This review aims to investigate the role of probiotics in modulating the gut microbiome and their potential therapeutic benefits in managing SLE, providing insights for future research and clinical practice.Methods: We conducted a thorough search for papers published up to June 2023 in databases such as PubMed/MEDLINE, Web of Science, Scopus, and Cochrane Library.Results: The systematic review identified 22 articles examining the effects of probiotics on SLE. These studies—which include in vivo tests, in vitro research, and clinical trials—indicate that probiotics may be effective against inflammation, and improve immunological responses and metabolic profiles in SLE patients. Most in vivo studies were assessed as medium to high quality, while the randomized controlled trial was deemed of high quality.Conclusion: According to the findings of our systematic review, probiotics may be used in conjunction with other treatments to manage SLE. Nonetheless, current data is limited, and more randomized controlled trials would be required to fully examine their effectiveness.

1 September 2024 in Recent Patents on Anti-Cancer Drug Discovery
Verified
Journal Article
Closed access
PDF file
SZSeyed Mahdi Zarezadeh
Seyed Mahdi Zarezadeh
ASAmir Mohammad Sharafi
Amir Mohammad Sharafi
Gisou ErabiGisou Erabi
Gisou Erabi
ATArefeh Tabashiri
Arefeh Tabashiri
NTNavid Teymouri
Navid Teymouri
NDNiloofar Deravi
Niloofar Deravi
Cancer is one of the leading causes of mortality and morbidity worldwide, affecting millions of people physically and financially every year. Over time, many anticancer treatments have been proposed and studied, including synthetic compound consumption, surgical procedures, or grueling chemotherapy. Although these treatments have improved the daily life quality of patients and increased their survival rate and life expectancy, they have also shown significant drawbacks, including staggering costs, multiple side effects, and difficulty in compliance and adherence to treatment. Therefore, natural compounds have been considered a possible key to overcoming these problems in recent years, and thorough research has been done to assess their effectiveness. In these studies, scientists have discovered a meaningful interaction between several natural materials and signal transducer and activator of transcription 3 molecules. STAT3 is a transcriptional protein that is vital for cell growth and survival. Mechanistic studies have established that activated STAT3 can increase cancer cell proliferation and invasion while reducing anticancer immunity. Thus, inhibiting STAT3 signaling by natural compounds has become one of the favorite research topics and an attractive target for developing novel cancer treatments. In the present article, we intend to comprehensively review the latest knowledge about the effects of various organic compounds on inhibiting the STAT3 signaling pathway to cure different cancer diseases.

3 October 2023 in Health Science Reports
Verified
Journal Article
Open access
AFArezoo Faridzadeh
Arezoo Faridzadeh
YYYaser Yadegari
Yaser Yadegari
MBMahdi Bakhshaee
Mahdi Bakhshaee
MKMona Kabiri
Mona Kabiri
MMMozhgan Mohammadi
Mozhgan Mohammadi
FAFarahzad Jabbari Azad
Farahzad Jabbari Azad
Introduction: Allergic rhinitis (AR) is a prevalent chronic disease affecting a significant portion of the global population. The substantial economic burden associated with treating AR necessitates the exploration of alternative therapies. Probiotics have gained attention due to their availability, minimal adverse effects, and cost‐effectiveness. The present study aims to investigate the role of synbiotics as adjunctive agents in the treatment of AR when added to standard treatment.Method: Thirty patients with persistent allergic rhinitis (PAR) were randomly assigned to receive routine diet therapy plus synbiotics or routine diet therapy plus placebo per day for 4 months. The data analysis was conducted using SPSS Version 20.Result: This study revealed a notable difference in immunoglobulin (Ig)E levels between the placebo and synbiotics groups (p = 0.035) following the intervention. Although a statistically significant difference (p = 0.039) was observed in the changes before and after the intervention (synbiotics and placebo) in the SNOT22 questionnaire, this finding was not observed for the MiniRQLQ questionnaire. For the MiniRQLQ questionnaire, the within‐group analysis showed significant changes in activity variables (p = 0.023), ocular symptoms (p = 0.036), and practical problems (p = 0.043) exclusively in the synbiotics group. Additionally, changes in nasal symptoms were observed in both synbiotics (p = 0.006) and placebo (p = 0.007) groups.Conclusion: This study suggests that synbiotics supplementation for 4 months can impact IgE levels compared with placebo in individuals with PAR, while also exhibiting positive effects on symptomology.

8 February 2024 in Health Science Reports
Verified
Journal Article
Open access
Gisou ErabiGisou Erabi
Gisou Erabi
AFArezoo Faridzadeh
Arezoo Faridzadeh
APAli Parvin
Ali Parvin
NDNiloofar Deravi
Niloofar Deravi
MRMohammad Rahmanian
Mohammad Rahmanian
NRNima Rezaei
Nima Rezaei
Background and Aim: In late 2021, the world faced the rapid spread of the SARS‐CoV‐2 Omicron variant, which quickly became the variant of concern. In April 2022, two new lineages of Omicron (BA.4/BA.5) emerged from Africa, where they caused the fifth wave of infection. Method: We searched PubMed, Google Scholar, and Scopus online databases up to December 2023 for founding relevant studies. Results: BA.4 and BA.5 subgroups, with changes in the spike protein, have a greater ability to escape from the immune system, which was possible with the help of L452R and F486V mutations. Epidemiologically, these evolving subtypes show similarities to seasonal influenza but with higher mortality rates. The symptoms of these subgroups are different from the previous types in the form of upper respiratory symptoms. Antiviral treatments, the use of antibodies such as bebtelovimab, and the development of vaccines are promising. Conclusion: Consequently, we must continue to be vigilant in our joint surveillance efforts against COVID‐19 in diagnosis and treatment.

22 October 2024 in Journal of Food Science
Verified
Journal Article
Closed access
ZMZahra Mirfeizi
Zahra Mirfeizi
MMMahmoud Mahmoudi
Mahmoud Mahmoudi
MJMohammad Hassan Jokar
Mohammad Hassan Jokar
MSMaryam Sahebari
Maryam Sahebari
ENElmira Noori
Elmira Noori
AFArezoo Faridzadeh
Arezoo Faridzadeh